AU2011285619B2 - Treatment of mitochondrial diseases with naphthoquinones - Google Patents

Treatment of mitochondrial diseases with naphthoquinones Download PDF

Info

Publication number
AU2011285619B2
AU2011285619B2 AU2011285619A AU2011285619A AU2011285619B2 AU 2011285619 B2 AU2011285619 B2 AU 2011285619B2 AU 2011285619 A AU2011285619 A AU 2011285619A AU 2011285619 A AU2011285619 A AU 2011285619A AU 2011285619 B2 AU2011285619 B2 AU 2011285619B2
Authority
AU
Australia
Prior art keywords
dione
methylnaphthalene
levels
methyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2011285619A
Other languages
English (en)
Other versions
AU2011285619A1 (en
Inventor
Andrew W. Hinman
Orion D. Jankowski
Guy M. Miller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PTC Therapeutics Inc
Original Assignee
PTC Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PTC Therapeutics Inc filed Critical PTC Therapeutics Inc
Publication of AU2011285619A1 publication Critical patent/AU2011285619A1/en
Application granted granted Critical
Publication of AU2011285619B2 publication Critical patent/AU2011285619B2/en
Assigned to BIOELECTRON TECHNOLOGY CORPORATION reassignment BIOELECTRON TECHNOLOGY CORPORATION Alteration of Name(s) of Applicant(s) under S113 Assignors: EDISON PHARMACEUTICALS, INC.
Assigned to PTC THERAPEUTICS, INC. reassignment PTC THERAPEUTICS, INC. Request for Assignment Assignors: BIOELECTRON TECHNOLOGY CORPORATION
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C50/00—Quinones
    • C07C50/26—Quinones containing groups having oxygen atoms singly bound to carbon atoms
    • C07C50/32—Quinones containing groups having oxygen atoms singly bound to carbon atoms the quinoid structure being part of a condensed ring system having two rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2011285619A 2010-08-06 2011-08-04 Treatment of mitochondrial diseases with naphthoquinones Ceased AU2011285619B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40104410P 2010-08-06 2010-08-06
US61/401,044 2010-08-06
PCT/US2011/046630 WO2012019029A2 (en) 2010-08-06 2011-08-04 Treatment of mitochondrial diseases with naphthoquinones

Publications (2)

Publication Number Publication Date
AU2011285619A1 AU2011285619A1 (en) 2013-03-07
AU2011285619B2 true AU2011285619B2 (en) 2016-12-01

Family

ID=45560075

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011285619A Ceased AU2011285619B2 (en) 2010-08-06 2011-08-04 Treatment of mitochondrial diseases with naphthoquinones

Country Status (10)

Country Link
US (1) US20130345312A1 (https=)
EP (1) EP2600857A4 (https=)
JP (2) JP6045494B2 (https=)
AU (1) AU2011285619B2 (https=)
BR (1) BR112013002877A2 (https=)
CA (1) CA2807507A1 (https=)
EA (1) EA201300215A1 (https=)
MX (1) MX2013001469A (https=)
SG (1) SG187744A1 (https=)
WO (1) WO2012019029A2 (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005033092A1 (en) 2003-09-19 2005-04-14 Galileo Pharmaceuticals, Inc. Chroman derivatives
EP2471530B1 (en) 2005-06-01 2017-01-11 Edison Pharmaceuticals, Inc. Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
US9278085B2 (en) 2006-02-22 2016-03-08 Edison Pharmaceuticals, Inc. Side-chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
WO2009061744A2 (en) 2007-11-06 2009-05-14 Edison Pharmaceuticals, Inc. 4- (p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases
EA023618B1 (ru) 2008-01-08 2016-06-30 Эдисон Фармасьютикалз, Инк. Производные (гет)арил-п-хинона для лечения митохондриальных болезней
WO2009111576A2 (en) 2008-03-05 2009-09-11 Edison Pharmaceuticals, Inc. 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES
WO2009158348A1 (en) 2008-06-25 2009-12-30 Edison Pharmaceuticals, Inc. 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases
EP2344142B1 (en) 2008-09-10 2024-06-26 PTC Therapeutics, Inc. Treatment of pervasive developmental disorders with redox-active therapeutics
EP2362726B1 (en) 2008-10-14 2018-08-08 Bioelectron Technology Corporation Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells
CA2741767C (en) 2008-10-28 2017-09-12 Ptc Therapeutics, Inc. Process for the production of alpha-tocotrienol and derivatives
PL2424495T3 (pl) 2009-04-28 2018-06-29 Bioelectron Technology Corporation Leczenie dziedzicznej neuropatii nerwów wzrokowych lebera i dominującego zaniku nerwu wzrokowego chinonami tokotrienolu
WO2012174286A1 (en) 2011-06-14 2012-12-20 Edison Pharmaceuticals, Inc. Catechol derivatives for treatment of oxidative stress diseases
JP2014520894A (ja) 2011-07-19 2014-08-25 エジソン ファーマシューティカルズ， インコーポレイテッド 非アルファトコトリエノールの存在下でのアルファトコトリエノールの選択的酸化のための方法
HUE033757T2 (en) 2012-07-12 2017-12-28 Khondrion Ip B V Chromanyl derivatives for treating mitochondrial disease
CA2883879A1 (en) 2012-09-07 2014-03-13 Edison Pharmaceuticals, Inc. Quinone derivatives for use in the modulation of redox status of individuals
EP3626252A1 (en) 2013-03-01 2020-03-25 Stealth Biotherapeutics Corp Methods and compositions for the prevention or treatment of barth syndrome
CN110339339A (zh) * 2013-03-01 2019-10-18 康德生物医疗技术公司 治疗线粒体疾病的方法
US10189830B2 (en) 2013-03-15 2019-01-29 Bioelectron Technology Corporation Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders
US9670170B2 (en) 2013-03-15 2017-06-06 Bioelectron Technology Corporation Resorufin derivatives for treatment of oxidative stress disorders
US9296712B2 (en) 2013-03-15 2016-03-29 Edison Pharmaceuticals, Inc. Resorufin derivatives for treatment of oxidative stress disorders
US9868711B2 (en) 2013-03-15 2018-01-16 Bioelectron Technology Corporation Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders
US10047395B2 (en) 2013-06-26 2018-08-14 Stealth Biotherapeutics Corp Methods and compositions for detecting and diagnosing diseases and conditions
CA2936146A1 (en) * 2014-01-06 2015-07-09 Stealth Biotherapeutics Corp Methods and compositions for preventing or treating dominant optic atrophy
AU2015364640B2 (en) 2014-12-16 2020-08-13 Ptc Therapeutics, Inc. Polymorphic and amorphous forms of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide
ES3033538T3 (en) 2015-10-08 2025-08-05 Khondrion Ip B V Novel compounds for treating mitochondrial disease
EP3390377B1 (en) 2015-12-16 2026-03-25 PTC Therapeutics, Inc. Improved methods for enriching alpha-tocotrienol from mixed tocol compositions
WO2017106803A1 (en) 2015-12-17 2017-06-22 Bioelectron Technology Corporation Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders
JP2018083799A (ja) 2016-11-15 2018-05-31 バイオエレクトロン テクノロジー コーポレイション ２−置換アミノ−ナフト［１，２−ｄ］イミダゾール−５−オン化合物またはその製薬学上許容される塩
KR102660473B1 (ko) 2017-04-05 2024-04-24 콘드리온 아이피 비.브이. 미토콘드리아 질환의 신규 치료
CN110582480B (zh) * 2017-04-21 2023-11-10 塔斯马尼亚大学 治疗化合物和方法
WO2020028222A1 (en) * 2018-07-29 2020-02-06 Musc Foundation For Research Development Compounds for the treatment of neurological or mitochondrial diseases
KR20210076956A (ko) 2018-10-17 2021-06-24 피티씨 테라퓨틱스, 인크. α-시누클레인병증, 타우병증 및 기타 장애를 억제 및 치료하기 위한 2,3,5-트리메틸-6-노닐사이클로헥사-2,5-디엔-1,4-디온
CN113473977A (zh) 2019-01-25 2021-10-01 巴塞罗那自治大学 用于治疗线粒体疾病用途的大麻二酚和/或其衍生物
CN114746430B (zh) 2019-10-04 2026-01-30 康德生物医疗有限公司 治疗线粒体异常疾病的伐替苯醌的醌-、氢醌-和萘醌-类似物
US12037350B2 (en) 2020-04-03 2024-07-16 Stealth Biotherapeutics Inc. Compositions and methods for the prevention and/or treatment of mitochondrial disease, including Friedreich's ataxia
IT202100006065A1 (it) * 2021-03-15 2022-09-15 Univ Degli Studi Padova Composto per l’uso nel metodo di trattamento delle malattie mitocondriali da disfunzione dei complessi i, ii, iii della catena respiratoria
PE20240893A1 (es) 2021-07-08 2024-04-24 Ptc Therapeutics Inc Composiciones farmaceuticas que comprenden 2,3,5-trimetil-6-nonilciclohexa-2,5-dien-1,4-diona

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060058398A1 (en) * 2002-01-31 2006-03-16 Hisamitsu Pharmaceutical Co., Inc. Medicinal compositions containing vitamin k's as nerve growth factor potentiator and utilization thereof
WO2006130775A2 (en) * 2005-06-01 2006-12-07 Edison Pharmaceuticals, Inc. Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomakers
WO2007100652A2 (en) * 2006-02-22 2007-09-07 Edison Pharmaceuticals, Inc. Side chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0117326D0 (en) * 2001-07-16 2001-09-05 Univ Aberdeen Napthoquinone-type inhibitors of protein aggregation
US20040087527A1 (en) * 2002-10-31 2004-05-06 Day Brian J. Methods for treatment of thiol-containing compound deficient conditions
RU2318500C2 (ru) * 2005-10-18 2008-03-10 Общество С Ограниченной Ответственностью "Митотехнология" Способ воздействия на организм путем адресной доставки биологически активных веществ в митохондрии, фармацевтическая композиция для его осуществления и соединение, применяемое для этой цели
KR20080047959A (ko) * 2006-11-27 2008-05-30 주식회사 엠디바이오알파 비만, 당뇨, 대사성 질환, 퇴행성 질환 및 미토콘드리아이상 질환의 치료 또는 예방을 위한 나프토퀴논계 약제조성물
WO2009111576A2 (en) * 2008-03-05 2009-09-11 Edison Pharmaceuticals, Inc. 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES
EP2344142B1 (en) * 2008-09-10 2024-06-26 PTC Therapeutics, Inc. Treatment of pervasive developmental disorders with redox-active therapeutics
US20110172312A1 (en) * 2009-12-31 2011-07-14 Miller Guy M Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones
EP2601168A4 (en) * 2010-08-06 2013-12-04 Ampere Life Sciences Inc TREATMENT OF MITOCHONDRIAL DISEASES BY VITAMIN K
WO2012170773A1 (en) * 2011-06-08 2012-12-13 Edison Pharmaceuticals, Inc. Adjunctive therapy for the treatment of mitochondrial disorders with quinones and naphthoquinones

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060058398A1 (en) * 2002-01-31 2006-03-16 Hisamitsu Pharmaceutical Co., Inc. Medicinal compositions containing vitamin k's as nerve growth factor potentiator and utilization thereof
WO2006130775A2 (en) * 2005-06-01 2006-12-07 Edison Pharmaceuticals, Inc. Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomakers
WO2007100652A2 (en) * 2006-02-22 2007-09-07 Edison Pharmaceuticals, Inc. Side chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers

Also Published As

Publication number Publication date
EP2600857A2 (en) 2013-06-12
EA201300215A1 (ru) 2013-07-30
AU2011285619A1 (en) 2013-03-07
BR112013002877A2 (pt) 2016-05-31
WO2012019029A3 (en) 2013-08-15
MX2013001469A (es) 2013-05-14
JP2016041772A (ja) 2016-03-31
CA2807507A1 (en) 2012-02-09
SG187744A1 (en) 2013-03-28
JP2013541502A (ja) 2013-11-14
EP2600857A4 (en) 2014-06-11
JP6045494B2 (ja) 2016-12-14
WO2012019029A2 (en) 2012-02-09
US20130345312A1 (en) 2013-12-26

Similar Documents

Publication Publication Date Title
AU2011285619B2 (en) Treatment of mitochondrial diseases with naphthoquinones
US20140031432A1 (en) Treatment of mitochondrial diseases with vitamin k
US9447006B2 (en) Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
US9296712B2 (en) Resorufin derivatives for treatment of oxidative stress disorders
US7432305B2 (en) Tail variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
US9464016B2 (en) Catechol derivatives for treatment of oxidative stress diseases
US9868711B2 (en) Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders
WO2012170773A1 (en) Adjunctive therapy for the treatment of mitochondrial disorders with quinones and naphthoquinones
JP2015533794A (ja) 酸化ストレス障害を処置するためのベンゾキノン誘導体
US20140275045A1 (en) Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders
HK1173364B (en) Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
HK1182941A (en) Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
HK1108651B (en) Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
HK1173364A (en) Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
HK1182940A (en) Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
HK1112585A (en) Tail variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: BIOELECTRON TECHNOLOGY CORPORATION

Free format text: FORMER NAME(S): EDISON PHARMACEUTICALS, INC.

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: PTC THERAPEUTICS, INC.

Free format text: FORMER OWNER(S): BIOELECTRON TECHNOLOGY CORPORATION

MK14 Patent ceased section 143(a) (annual fees not paid) or expired